Skip to main content

Millipore, Invirion Diagnostics, Guava Technologies

Millipore has released its GPCRProfiler screening technology for selectivity screening, lead compound characterization, and focused GPCR library screening.
According to the company, the tool “more accurately characterizes lead compounds than traditional binding methods by providing comprehensive functional data that enables pharmaceutical and biotechnology companies to accelerate their lead optimization efforts.”

Invirion Diagnostics this week released its latest reagent kit, the ViroTect HCV In-Cell Detection Kit. It is intended for researchers in the health sciences sectors who are studying cells infected with the hepatitis C virus.
The assay is designed to detect HCV RNA in cells from individuals infected with HCV or in cell lines infected with HCV. The assay will provide new insights into the pathology of the disease and into the efficacies of the drugs that are being developed to treat hepatitis C.
The Invirion ViroTect HCV kit is based on the company's proprietary technology for labeling specific viral RNA's inside cells. Since viruses typically live inside cells, Invirion's assays provide a unique and powerful method for studying viral replication in the cells that they infect and for determining if active viral replication is or is not inhibited by the drugs that are used to treat disease caused by the virus.
Invirion also makes kits for the monitoring of HIV replication in cells and the detection of HPV E6, E7 mRNA for cervical cancer screening.

Guava Technologies has released the new Guava EasyCyte Plus System, a flow cytometry and cell counting-analyzer. The system will be launched at the NIH Research Festival in Washington, DC, on Oct. 19 and 20.
The instrument has a fourth color option that, when combined with the built-in 96-well autosampler, allows researchers “to obtain even more data while performing more complex biological studies such as white blood cell phenotyping, cell signaling, cytokine production, activation marker analysis, and multiplex compound screening,” Guava said in a statement.
This, in turn, enables researchers “to monitor the interplay of up to four different biological mechanisms at the same time, improving the efficiency of experimental outputs.”

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.